Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Bauer Website

Thomas R. Bauer Jr., Ph.D.

Portait Photo of Thomas Bauer
Experimental Transplantation and Immunology Branch
Molecular Oncology and Gene Transfer Section
Staff Scientist
Center for Cancer Research
National Cancer Institute
10 Center Dr, MSC1203
Bldg 10-CRC, Rm 3-3264
Bethesda, MD 20892-1203
Phone:  
301-435-7125
Fax:  
301-402-5054
E-Mail:  
bauert@mail.nih.gov

Biography

Born in Southwestern PA, but raised during my formative years in the suburbs of Los Angeles, I left SoCal for Indiana, where I received a B.S. in Microbiology from the University of Notre Dame in 1985. Desiring warmer weather, I went to the University of Miami (Florida), where I received a Ph.D. in Microbiology and Immunology in 1992 studying human immunoglobulin lambda light chain genes. From there, I joined the laboratory of Dennis Hickstein in Seattle, where I was a postdoc and later acting instructor, working on LAD and CD18, and to my current position as Staff Scientist at the NIH.

Research

For over a decade, our lab has been working towards gene therapy of the childhood immunodeficiency disease 'Leukocyte Adhesion Deficiency', also known as LAD. Patients with LAD have defects in their leukocyte integrin CD18 gene, which leads to defective leukocytes unable to adhere to and migrate to sites of bacterial infection. Although hematopoietic stem cell transplantation can cure LAD patients, too few patients have suitable transplantation donors. We have investigated the possibility of transferring a functional copy of the CD18 gene into patients' hematopoietic stem cells using gene transfer with retroviral vectors. Towards this end, we have utilized an animal model of LAD in dogs, know as 'canine Leukocyte Adhesion Deficiency' or CLAD to investigate the various vectors and conditions required for successful gene transfer. We have shown that by using gene transfer of the canine CD18, we are able to correct the CD18 defect in canine leukocytes both in vitro and in vivo, leading to dogs free of their CLAD disease.

This page was last updated on 3/5/2014.